Liver transplantation (LT) has a demonstrated survival benefit in select patients with severe acute alcoholic hepatitis (SAH) who do not respond to steroids, but prior studies suggest low adoption among US LT centers. Our study explored current perceptions and practice patterns of LT for SAH in the United States. We administered a Web-based survey to medical directors of US LT centers between May and October of 2017 to characterize practice patterns and perceptions of LT for SAH. We obtained responses from 45 (41.3%) of 109 surveyed centers, representing all 11 (100%) United Network for Organ Sharing regions. Half (n = 23; 51.1%) reported performing at least 1 LT for SAH, although most (n = 19; 82.6%) of those had performed ≤5 LTs for that indication. Centers expressed near consensus for selection criteria, requiring strong social support (100%), no prior presentations with SAH (91.3%), absence of a severe coexisting psychiatric disorder (91.3%), and official psychosocial evaluation (87.0%). Reported posttransplant survival of SAH patients was excellent, with 17 (73.9%) centers reporting 1-year posttransplant survival exceeding 90%. Among centers that had not performed LT for SAH, the most commonly cited reason was perceived high risk of alcohol relapse. In conclusion, our data demonstrate that LT is increasingly adopted as a therapeutic intervention for patients with SAH and that careful selection allows for excellent 1-year posttransplant survival. Despite this, nearly half of US centers do not perform LT for this indication due to perceived high risk of alcohol relapse. Our data support the use of LT for well-selected patients with SAH.
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Alcoholic liver disease (ALD) is a major cause of alcohol-related morbidity and mortality and is the second most common indication for liver transplantation (LT) in both the United States and Western Europe. (1, 2) Acute alcoholic hepatitis is a distinct clinical syndrome among patients with ALD characterized by rapid-onset jaundice and liver injury with a high 28-day mortality ranging from 30% to 50%. (3) Severe acute alcoholic hepatitis (SAH), defined by Model for End-Stage Liver Disease (MELD) > 20 or Maddrey discriminant function > 32 carries a worse short-term prognosis and limited therapeutic options. (4) Steroids are the mainstay of therapy for these patients (5) (6) (7) but are not effective in many patients. Steroid nonresponders, as defined by the Lille score, have an estimated 6-month mortality rate of 75%. (8) For these patients, LT has historically been a controversial therapeutic option because SAH is typically preceded by recent alcohol consumption, raising concerns about potential alcohol relapse after transplant, nonadherence with clinic follow-up and immunosuppression, decreased graft survival, and, on a broader scale, reduced organ donation due to societal reservations about allograft allocation to patients with SAH.
A landmark study in 2011 demonstrated a survival benefit of LT in carefully selected patients with SAH who were not responsive to steroids. The 6-month survival of transplanted patients was 77% compared with only 23% in matched nontransplanted controls. (9) Despite these promising data, a survey in the United States 3 years later found that only 27% of transplant centers listed any patients with SAH for LT, accounting for 1.4% of all transplants performed nationally. (10) Notably, of the 33 centers that were not transplanting for SAH at that time, one-third reported "no challenges" to LT for SAH, suggesting the possibility that it would be considered in the future. (10) Anticipating a changing landscape, the aim of our study was to examine changes in practice patterns and outcomes of LT for SAH 3 years later, and further, to characterize perceptions and opinions about its role in the treatment of SAH.
Patients and Methods
A list of transplant centers was obtained from the Scientific Registry of Transplant Recipients Web site. Pediatric centers and centers with low transplant volumes (<5 LTs per year) were excluded. The survey was distributed to the medical director of the program or lead transplant hepatologist, as identified by the program Web site. The study was approved by the institutional review board at UT Southwestern Medical Center.
A 16-item questionnaire was developed to characterize practice patterns and perceptions of LT for SAH at each institution (Supporting Materials). Questions were adapted from earlier surveys when available. (10) After survey development, it was pretested among 7 providers, with each provider completing a cognitive interview about the survey after completion. The survey was created in Research Electronic Data Capture and distributed via e-mail between May 2017 and October 2017. Providers that did not respond were sent up to 3 e-mail reminders at monthly intervals.
Chi-squared and Fisher's exact tests were used to perform group comparisons between responders and nonresponders as well as centers that had and had not transplanted for SAH. Ordinal data were compared via creation of quintiles, which were then compared with chi-squared analysis. Continuous variables were compared with Levene's test for equal variances and the Fisher's exact test. Statistical significance was defined as P < 0.05. All data analysis was performed using SPSS, version 25 (IBM, Armonk, NY).
Results
Of the 109 LT centers that received surveys, 45 (41.3%) returned completed surveys. Responses represented each of the 11 United Network for Organ Sharing (UNOS) regions. Responders did not significantly differ in age of transplant program, number of LTs performed per year, MELD at the time of transplant, or posttransplant graft survival. A total of 23 (51.1%) centers reported performing at least 1 transplant for SAH. Centers that had and had not transplanted for SAH did not significantly differ in age of the transplant program, number of transplants performed per year (by data from the scientific registry of transplant recipients and self-reported data), MELD at time of transplant, or posttransplant graft survival (Table 1) .
There was no difference in LT listing criteria required of alcoholic patients with cirrhosis between centers that had and had not transplanted for SAH (Table 2) . Although centers that did not transplant for SAH were more likely to require 7-9 months of abstinence prior to LT for alcoholic cirrhosis, the majority of all centers (n = 36; 80%) require 3-6 months of sobriety. Additionally, centers that had and had not transplanted for SAH did not differ in their perceived benefit of a 6-month sobriety period, with both groups most commonly reporting that it allows for improvement in hepatic function (Table 3) .
Most of the 23 centers that had performed transplantation for SAH had performed 5 or fewer tranplants for this indication: 11 (47.8%) centers had transplanted 1-2 SAH patients, 8 (34.8%) had transplanted 3-5 patients, 2 (8.7%) had transplanted 6-10 patients, and 2 (8.7%) centers had transplanted >10 SAH patients (Fig. 1) . The majority of these centers (n = 14; 60.9%) evaluated 20% or fewer patients with SAH for LT. Of those who were evaluated, even fewer were listed: 15 (65.2%) centers reported listing fewer than 20% of patients who were evaluated. However, the likelihood of undergoing 
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LT once listed for transplant varied between centers. A total of 9 (39.1%) centers reported that >60% of listed SAH patients underwent LT, while 8 (34.8%) centers reported that 20% or fewer underwent LT. There was near consensus for LT selection criteria including requiring a strong social support system (n = 23, 100%), no prior presentations with SAH (n = 21, 91.3%), absence of a severe coexisting psychiatric disorder (n = 21, 91.3%), and completion of an official psychosocial evaluation (n = 20, 87.0%). Interestingly, less than two-thirds (n = 14, 60.9%) required the patient to have been previously unaware of having chronic liver disease.
Although 82.4% of centers offered regular social work follow-up for patients with SAH, only 41% offered support group therapy via the transplant center and only 21% encouraged patients to attend external support groups. Additionally, only half reported offering regular psychologist/psychiatry follow-up. Reported posttransplant survival of SAH patients was excellent, with 17 (73.9%) centers reporting 1-year posttransplant survival exceeding 90% and 3 (13.0%) centers reporting 81%-90% survival. One center reported 1-year survival of <60%, but this center had only performed 1 LT for SAH (Fig. 2) .
Of the 22 centers that had never performed LT for SAH, 16 (72.7%) indicated that they would not consider LT for SAH patients in the near future. The most commonly cited reasons were high risk of relapse NOTE: Data are given as mean ± standard deviation and n (%). NOTE: Data are given as n (%). One center that did not perform transplantation for SAH selected "other" and reported requiring a social work evaluation prior to listing.
(n = 9, 41.0%), insufficient period of abstinence from alcohol (n = 6, 27.3%), and possibility of spontaneous liver function recovery with abstinence (n = 4, 18.2%). Only 1 (4.5%) center was concerned about poor posttransplant outcomes in patients with SAH, and no centers were concerned about fear of public recrimination.
One center indicated they have a protocol for selecting patients but have not found a patient who fulfilled the protocol.
Discussion
Our survey study explored practice patterns and attitudes of LT centers in the United States with respect to LT for SAH. We found that over half of the centers had transplanted at least 1 patient for SAH, reflecting an increased willingness to transplant for SAH since 2015, when only 27% of centers reported transplanting for this indication. (10) Nonetheless, the majority of centers reserved transplantation for select patients with SAH and reported evaluating <20% of SAH patients, listing <20% of evaluated patients, and ultimately performing 5 or fewer transplants for this indication. A total of 90% of centers reported 1-year posttransplant survival exceeding 80%, demonstrating continued excellent posttransplant outcomes even with markedly increased adoption of LT for SAH. The potential survival benefit of LT in well-selected patients with SAH who are nonresponsive to steroids was first reported by Mathurin et al. in 2011. (9) Since that time, several studies have confirmed the survival benefit of LT for SAH in other centers, including the United States. One single-center study demonstrated 6-month survival of 89% for patients after LT compared with 11% for matched controls, (11) and a multicenter study demonstrated posttransplant 1-year and 3-year survival rates of 94% and 84%, respectively. (12) LT centers in our study also reported favorable survival rates, with the majority reporting 1-year survival rates exceeding 90%. This excellent posttransplant survival is likely in large part due to stringent selection of patients. Most transplant centers reported being very selective, evaluating fewer than 20% of patients with SAH for transplant, and only 4% of patients who presented with SAH underwent LT. Nearly all centers 
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that transplanted for SAH required first presentation with SAH, a strong social support system, and an official psychosocial evaluation prior to listing for transplant. These selection criteria replicated those used in the original Mathurin et al. study, (9) strengthening the idea that well-selected patients with SAH can achieve excellent 1-year and 3-year survival after transplant in clinical practice. These posttransplant survival data are comparable to outcomes of LT performed for other types of liver disease, (13) which is encouraging and provides continued evidence that LT can be performed safely for SAH. Still, 48% of transplant centers reported not transplanting for SAH, and of these, 72% reported that they would not consider transplanting for SAH in the near future. The concern for relapse is the most commonly cited reason for not transplanting for SAH, and over half of surveyed centers perceive a 6-month abstinence period to be beneficial in decreasing recidivism. Almost all centers that did not transplant for SAH felt the 6-month period allows for improvement in liver function, and half felt this period decreases recidivism and prevents adverse public opinion. These findings provide insight into the challenges associated with expansion of LT for SAH and describe common opinions across transplant centers that have not previously been described. However, it is not clear that 6 months of abstinence successfully addresses the concerns of transplant centers. Regarding recovery of liver function, Veldt et al. found that patients with Child-Pugh class C alcoholic cirrhosis without improvement in liver function after 3 months of abstinence from alcohol were unlikely to have any subsequent improvement. (14) In practice, the Lille score can identify patients with SAH with a high short-term mortality who are unlikely to improve by day 7 after presentation, and a combination of the MELD and Lille scores can predict 2-and 6-month survival rates. (8, 15) This suggests that a 6-month duration may not be necessary to determine which patients will experience spontaneous recovery of liver function.
Furthermore, public opinion of LT for SAH is evolving, mitigating concerns that use of organs for patients with SAH will result in a decrease in the donor pool. Notably, while half of the centers that do not transplant for SAH stated that preventing adverse opinion was part of their rationale for waiting 6 months, none of these centers indicated that public recrimination was part of their rationale for not transplanting in the future. A survey in 2015 revealed the general public is at least neutral on the topic of early LT for SAH, and 74% of subjects would not hesitate to donate organs regardless of the manner of organ allocation. (16) (17) (18) A commonly discussed phenomenon was the "Best effect," which refers to a decrease in LTs in the United Kingdom between 2003 and 2004 following the heavily publicized return to alcoholism after LT of a famed footballer, George Best. Although the concern regarding public perception is acknowledged, in this case, the LT numbers declined for 1 year and then subsequently rose again. Similarly, LT being offered to acetaminophen overdoses or to patients with acute hepatitis B infection due to intravenous drug use has not decreased willingness to donate organs. (17, 18) Regarding the concern about recidivism, the ability of a pretransplant abstinence period to predict posttransplant behavior has been studied extensively and has yielded inconclusive findings. Some studies have shown longer pretransplant abstinence duration predicted decreased rates of relapse while shorter durations predicted problem drinking after transplant. (19) However, this trend is not clearly seen across all studies. (20) (21) (22) The following criteria have been shown to predict posttransplant relapse more accurately than duration of sobriety and better reflect the complex nature of ALD: presence of psychiatric comorbidity, (23, 24) lack of social support, (20, 25) nonacceptance of having an alcohol problem, (26) and presence of a first-degree relative with alcohol use disorder. (27) The studies by Mathurin et al. and Im et al. both demonstrated low rates of relapse in patients after transplant for SAH. (9, 11) A uniform 6-month rule is imperfect in that it includes patients who relapse and excludes those who do not; careful patient selection such as those used in SAH protocols may identify those who would benefit with an acceptable risk of relapse. (28) It is worth noting that, even with the good outcomes reported, few centers offered pretransplant and posttransplant support to address the underlying alcohol use disorder. Although most centers offered social work follow-up, less than half offered support group therapy or encouraged patients to attend external support groups. A comparison could be made to postpercutaneous coronary intervention care: This would be analogous to a cardiologist placing a coronary artery stent and then neglecting to address the underlying hypertension, dyslipidemia, and diabetes after the intervention. If high-intensity posttransplant alcohol cessation care was provided, the already excellent outcomes may be improved further.
We acknowledge our study has potential limitations. Survey studies are inherently limited by response bias, in which respondents answer questions reflecting how they should practice instead of actual practices. There is also a possibility of nonresponse bias, with centers that had an increased interest in LT for SAH more likely to respond than centers without transplant protocols for SAH. However, we had a response rate exceeding 40%, and responses reflected each of the UNOS regions. Furthermore, we did not find any differences in characteristics between responders and nonresponders.
In summary, our study highlights that LT for SAH is being increasingly accepted in the United States. (10) Most transplant centers continue to reserve this for well-selected patients and, therefore, observe excellent 1-year posttransplant survival. Still, nearly half of US centers do not peform LT for this indication, and concern for alcohol relapse remains the most common barrier to increased adoption of LT for SAH. Our data support the use of LT for well-selected patients with SAH as the practice continues to expand. Repeat surveys will likely be useful in the future to continue to track transplant center opinions on this evolving field.
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